Previous 10 | Next 10 |
2024-05-08 06:55:36 ET Summary Ascendis Pharma is expected to achieve cash flow break even by the end of 2024, driven by its core franchise of medicines for rare endocrinology conditions. The company's approved drug, Skytrofa, has shown strong sales and has the potential to be a b...
2024-05-06 13:31:49 ET More on AstraZeneca, Cellectis, etc. AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market AstraZeneca PLC (AZN) Q1 2024 Earnings Call Transcript Novo, Teva, AstraZeneca issued FTC warnings over ...
Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) a clinical-stage biote...
2024-05-04 15:30:00 ET Read the full article on Seeking Alpha For further details see: Pharma R&D productivity seen improving for the first time in years - Deloitte
2024-05-03 10:28:54 ET More on Amgen Amgen, Inc. (AMGN) Q1 2024 Earnings Call Transcript Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet Amgen: I Prefer To Chase Value And Dividends Biggest stock movers today: WOW, AAPL, SQ, and more Amge...
2024-05-02 14:31:50 ET More on Novartis, Novartis AG, etc. Novartis AG (NVS) Q1 2024 Earnings Call Transcript Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results Novartis AG 2024 Q1 - Results - Earnings Call Presentation Novartis to b...
First BTK inhibitor to show favorable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s CALQUENCE ® (acalabrutinib) in comb...
2024-05-01 14:41:05 ET Summary Eli Lilly and Company's revenue for the first quarter of 2024 fell short of analysts' expectations, but the company exceeded forecasts on the bottom line. Sales of the company's obesity and diabetes drugs, particularly Mounjaro and Zepbound, saw sign...
New data for TEZSPIRE and BREZTRI demonstrate AstraZeneca’s innovation and commitment to transform care in COPD AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Socie...
2024-04-30 12:18:17 ET More on AstraZeneca, GSK, etc. AstraZeneca: A Triple Shot Of Income, Growth, And Value Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy AstraZeneca: Strong In A Weak Market GSK Q1 2024 Earnings Preview Ast...
News, Short Squeeze, Breakout and More Instantly...
2024-07-20 00:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 08:30:07 ET Jefferies analyst issues HOLD recommendation for AZN on July 2, 2024 06:20AM ET. The previous analyst recommendation was Hold. AZN was trading at $77.94 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...